Back to top
more

TESARO, Inc. (TSRO)

(Delayed Data from NSDQ)

$74.96 USD

74.96
NA

0.00 (0.00%)

Updated Jan 18, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Implied Volatility Surging for Tesaro (TSRO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Tesaro (TSRO) stock based on the movements in the options market lately.

AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting

by Zacks Equity Research

AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.

Glaxo, Pfizer to Merge Consumer Health Units, Form New JV

by Zacks Equity Research

Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.

Company News For Dec 4, 2018

by Zacks Equity Research

Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT

Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%

by Zacks Equity Research

Glaxo (GSK) announces definitive deal to buy TESARO.

TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer

by Zacks Equity Research

TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.

Tesaro (TSRO) Up 45.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Tesaro (TSRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up

by Zacks Equity Research

Clovis Oncology's (CLVS) shares rise more than 5% following the issuance of a new patent for Rubraca in the United States for claims related to methods of treating cancer with its high dosage strength.

TESARO Shares Rally on Rumors of Potential Acquisition Offer

by Zacks Equity Research

Per a Bloomberg report, TESARO (TSRO) may have received an acquisition offer. Shares rally on rumors.

TESARO (TSRO) Jumps: Stock Rises 5.4%

by Zacks Equity Research

TESARO (TSRO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

by Zacks Equity Research

PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.

AstraZeneca's Lynparza Gets Priority Review in 1st Line Use

by Zacks Equity Research

AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.

Do Options Traders Know Something About TESARO (TSRO) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to TESARO (TSRO) stock based on the movements in the options market lately.

TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up

by Zacks Equity Research

TESARO (TSRO) beats estimates for earnings in the third quarter but misses the same on revenues. Zejula sales maintain momentum.

Tesaro (TSRO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tesaro (TSRO) delivered earnings and revenue surprises of 4.96% and -7.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Clovis (CLVS) Q3 Earnings & Sales Lag, Rubraca Disappoints

by Zacks Equity Research

Clovis (CLVS) misses estimates in the third quarter for both earnings and sales and guides lower sales for only marketed drug, Rubraca in Q4. Shares decline.

Tesaro (TSRO) Q3 Earnings Preview: What to Watch Ahead of the Release

by Zacks Equity Research

Tesaro (TSRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Tesaro (TSRO) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Tesaro (TSRO) stock based on the movements in the options market lately

    Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC

    by Zacks Equity Research

    Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.

      Here's Why J&J (JNJ) is a Good Bet in a Troubled Market

      by Zacks Equity Research

      A diversified portfolio, robust pipeline, strong growth of new drugs and a consistent dividend payout make Johnson & Johnson (JNJ) a good bet amid market turmoil as well as over the long term.

        Options Traders Expect Huge Moves in Tesaro (TSRO) Stock

        by Zacks Equity Research

        Investors need to pay close attention to Tesaro (TSRO) stock based on the movements in the options market lately.

          Pharma/Biotech Stocks to Watch This Prostate Cancer Month

          by Zacks Equity Research

          Here we highlight a few companies that are focused on developing treatments for prostate cancer.

            Tesaro (TSRO) Surges: Stock Moves 5.5% Higher

            by Zacks Equity Research

            Tesaro (TSRO) shares rose nearly 6% in the last trading session, amid huge volumes.

              Is the Options Market Predicting a Spike in Tesaro (TSRO) Stock?

              by Zacks Equity Research

              Investors need to pay close attention to Tesaro (TSRO) stock based on the movements in the options market lately.

                Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Beat

                by Zacks Equity Research

                Clovis (CLVS) misses bottom-line estimates in the second quarter but beats on the top line. Rubraca sales increase.